8,500 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Buck Wealth Strategies LLC

Buck Wealth Strategies LLC acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,500 shares of the biotechnology company’s stock, valued at approximately $221,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its holdings in Exelixis by 16.6% in the third quarter. Victory Capital Management Inc. now owns 136,178 shares of the biotechnology company’s stock worth $3,534,000 after buying an additional 19,372 shares during the last quarter. Entropy Technologies LP acquired a new position in Exelixis during the third quarter valued at approximately $475,000. Los Angeles Capital Management LLC grew its holdings in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Covestor Ltd grew its holdings in Exelixis by 5.7% during the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 341 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in Exelixis during the third quarter valued at approximately $577,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on EXEL. TD Cowen increased their price target on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a report on Monday, October 21st. Guggenheim increased their price target on Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. Morgan Stanley boosted their target price on shares of Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, October 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Exelixis in a research report on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.44.

Insider Activity at Exelixis

In related news, EVP Dana Aftab sold 96,986 shares of Exelixis stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $17,463,075. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the completion of the sale, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 96,986 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $17,463,075. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 248,148 shares of company stock valued at $8,042,547 over the last ninety days. 2.85% of the stock is owned by insiders.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $35.85 on Wednesday. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.60. The company’s fifty day moving average is $28.48 and its 200-day moving average is $24.92. The company has a market capitalization of $10.24 billion, a PE ratio of 22.98, a P/E/G ratio of 0.92 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the previous year, the business posted $0.10 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, analysts forecast that Exelixis, Inc. will post 1.68 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.